These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 28704854)

  • 1. Switching from Premixed Insulin To Basal Insulin Analogue For Type 2 Diabetes and Role of Dipeptidyl Peptidase-4 Inhibitors.
    Gómez-Peralta F; Abreu C; Mora-Navarro G; López-Morandeira P; Pérez-Gutierrez E; Cordero-García B; Brito-Sanfiel M
    Exp Clin Endocrinol Diabetes; 2018 May; 126(5):268-276. PubMed ID: 28704854
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Glycaemic control in patients with type 2 diabetes switching from premixed insulin to long-acting basal insulin analogue plus oral antidiabetic drugs: an observational study.
    Gómez-Peralta F; Carramiñana-Barrera F; Félix-Redondo FJ; Fraile-Gómez J;
    Int J Clin Pract; 2012 Oct; 66(10):959-68. PubMed ID: 22994330
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and treatment satisfaction of once-daily insulin glargine plus one or two oral antidiabetic agents versus continuing premixed human insulin in patients with type 2 diabetes previously on long-term conventional insulin therapy: the Switch pilot study.
    Schiel R; Müller UA
    Exp Clin Endocrinol Diabetes; 2007 Nov; 115(10):627-33. PubMed ID: 18058596
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combination therapy with DPP-4 inhibitors and insulin in patients with type 2 diabetes mellitus: what is the evidence?
    Charbonnel B; Schweizer A; Dejager S
    Hosp Pract (1995); 2013 Apr; 41(2):93-107. PubMed ID: 23680741
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and treatment satisfaction of once-daily insulin glargine plus one or two oral antidiabetic agents versus continuing premixed human insulin in patients with Type 2 diabetes previously on long-term conventional insulin therapy: the SWITCH Pilot Study.
    Schiel R; Müller UA
    Exp Clin Endocrinol Diabetes; 2008 Jan; 116(1):58-64. PubMed ID: 17973208
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Patients with type 2 diabetes inadequately controlled on premixed insulin: effect of initiating insulin glargine plus oral antidiabetic agents on glycaemic control in daily practice.
    Hammer H; Klinge A
    Int J Clin Pract; 2007 Dec; 61(12):2009-18. PubMed ID: 17997807
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A prospective study to optimize insulin treatment by switching to insulin glargine in type 2 diabetic patients previously uncontrolled on premixed insulin: the optimization study.
    Yang W; Lv X; Li Q; Jia W; Tian H
    Curr Med Res Opin; 2012 Apr; 28(4):533-41. PubMed ID: 22449098
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, in patients with type 2 diabetes mellitus inadequately controlled on glimepiride alone or on glimepiride and metformin.
    Hermansen K; Kipnes M; Luo E; Fanurik D; Khatami H; Stein P;
    Diabetes Obes Metab; 2007 Sep; 9(5):733-45. PubMed ID: 17593236
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor PF-734200 added to metformin in Type 2 diabetes.
    Rosenstock J; Lewin AJ; Norwood P; Somayaji V; Nguyen TT; Teeter JG; Johnson SL; Dai H; Terra SG
    Diabet Med; 2011 Apr; 28(4):464-9. PubMed ID: 21392067
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Switching from premixed insulin to basal-bolus insulin glargine plus rapid-acting insulin: the ATLANTIC study.
    Mathieu C; Storms F; Tits J; Veneman TF; Colin IM
    Acta Clin Belg; 2013; 68(1):28-33. PubMed ID: 23627191
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Healthcare costs of the combination of metformin/dipeptidyl peptidase-4 inhibitors compared with metformin/other oral antidiabetes agents in patients with type 2 diabetes and metabolic syndrome.
    Sicras-Mainar A; Navarro-Artieda R
    Diabetes Technol Ther; 2014 Nov; 16(11):722-7. PubMed ID: 25089916
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of once-daily insulin detemir on oral antidiabetic drug (OAD) use in patients with type 2 diabetes.
    Vora J; Caputo S; Damci T; Orozco-Beltran D; Pan C; Svendsen AL; Sølje KS; Khunti K;
    J Clin Pharm Ther; 2014 Apr; 39(2):136-43. PubMed ID: 24329524
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Glycaemic efficacy of glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors as add-on therapy to metformin in subjects with type 2 diabetes-a review and meta analysis.
    Deacon CF; Mannucci E; Ahrén B
    Diabetes Obes Metab; 2012 Aug; 14(8):762-7. PubMed ID: 22471248
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Important differences in the durability of glycaemic response among second-line treatment options when added to metformin in type 2 diabetes: a retrospective cohort study.
    Mamza J; Mehta R; Donnelly R; Idris I
    Ann Med; 2016; 48(4):224-34. PubMed ID: 26982210
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Combination therapy of metformin vs dipeptidulpeptidase inhibitors and sulfonylureas in type 2 diabetes: clinical and economic impact].
    Sicras-Mainar A; Navarro-Artieda R
    Rev Peru Med Exp Salud Publica; 2014; 31(4):626-34. PubMed ID: 25597711
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The increased dipeptidyl peptidase-4 activity is not counteracted by optimized glucose control in type 2 diabetes, but is lower in metformin-treated patients.
    Fadini GP; Albiero M; Menegazzo L; de Kreutzenberg SV; Avogaro A
    Diabetes Obes Metab; 2012 Jun; 14(6):518-22. PubMed ID: 22171692
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effective switch from premixed to basal-prandial insulin to achieve glycemic goals in type 2 diabetes.
    Lavernia F
    Postgrad Med; 2010 May; 122(3):28-32. PubMed ID: 20463411
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of health policy and practice on finding the best fit for patients with type 2 diabetes after metformin failure: Croatian pilot study.
    Cigrovski Berković M; Herman Mahečić D; Gradišer M; Bilić-Ćurčić I
    Prim Care Diabetes; 2017 Jun; 11(3):265-272. PubMed ID: 28314484
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety and efficacy of vildagliptin: 52-week post-marketing surveillance of Japanese patients with type 2 diabetes in combination with other oral antidiabetics and insulin.
    Hayashi T; Murayama H; Shinfuku Y; Taniguchi T; Tsumiyama I; Oyama N
    Expert Opin Pharmacother; 2020 Jan; 21(1):121-130. PubMed ID: 31689132
    [No Abstract]   [Full Text] [Related]  

  • 20. Cardiovascular safety of combination therapies with incretin-based drugs and metformin compared with a combination of metformin and sulphonylurea in type 2 diabetes mellitus--a retrospective nationwide study.
    Mogensen UM; Andersson C; Fosbøl EL; Schramm TK; Vaag A; Scheller NM; Torp-Pedersen C; Gislason G; Køber L
    Diabetes Obes Metab; 2014 Oct; 16(10):1001-8. PubMed ID: 24827939
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.